Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3791892 | 0.82 | ALDH1A1 (0.60) | ALDH1A1MAPTSMN1; SMN2RORCMEN1 | |
| SCHEMBL20535682 | 0.80 | LMNA (0.56) | LMNAGAAALDH1A1POLBMAPT | |
| SCHEMBL28485570 | 0.80 | LMNA (0.56) | LMNAGAAALDH1A1POLBMAPT | |
| SCHEMBL8765733 | 0.80 | LMNA (0.56) | LMNAGAAALDH1A1POLBMAPT | |
| SCHEMBL8765742 | 0.80 | LMNA (0.61) | LMNAGAAALDH1A1POLBMAPT | |
| SCHEMBL10890401 | 0.78 | LMNA (0.54) | LMNAGAAALDH1A1MAPTHSD17B10 | |
| SCHEMBL3071609 | 0.78 | LMNA (0.71) | LMNAGAAALDH1A1POLBMAPT | |
| SCHEMBL4961590 | 0.78 | LMNA (0.53) | LMNAGAAALDH1A1POLBMAPT | |
| SCHEMBL3791417 | 0.77 | LMNA (0.58) | LMNAGAAALDH1A1MAPTRAB9A | |
| SCHEMBL2728856 | 0.77 | LMNA (0.58) | LMNAGAAALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263324-B1 | RADIOGRAPHIC ASSESSMENT OF TISSUE RESPONSE TO COMPOUNDS | VERITAS PHARMACEUTICALS (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20040170561-A1 | Functional radiographic imaging methods and agents | SALB JESSE (US) | 2004-09-02 | — | — | US | disclosed |
| US-6751290-B2 | Radiographic assessment of tissue after exposure to a compound | VERITAS PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-6723746-B2 | CELL MEMBRANE-PERMEABLE, RADIO-OPAQUE IMAGING AGENT | VERITAS PHARMACEUTICALS, INC. | 2004-04-20 | — | — | US | disclosed |
| EP-1263478-A2 | FUNCTIONAL RADIOGRAPHIC IMAGING METHODS AND AGENTS | Veritas Pharmaceuticals (US) | 2002-12-11 | — | — | EP | disclosed |
| EP-1263324-A2 | RADIOGRAPHIC ASSESSMENT OF TISSUE RESPONSE TO COMPOUNDS | Veritas Pharmaceuticals (US) | 2002-12-11 | — | — | EP | disclosed |
| EP-1263323-A2 | RADIOGRAPHIC ASSESSMENT OF TISSUE RESPONSE TO COMPOUNDS | Veritas Pharmaceuticals (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020039401-A1 | Radiographic assessment of tissue after exposure to a compound | VERITAS PHARMACEUTICALS, INC. | 2002-04-04 | — | — | US | disclosed |
| US-20010038682-A1 | Radiographic assessment of tissue response to compounds | VERITAS PHARMACEUTICALS INC., A DELAWARE CORP. | 2001-11-08 | — | — | US | disclosed |
| US-20010031035-A1 | Functional radiographic imaging methods and agents | VERITAS PHARMACEUTICALS INC. | 2001-10-18 | — | — | US | disclosed |
| WO-2001068151-A2 | FUNCTIONAL RADIOGRAPHIC IMAGING METHODS AND AGENTS | VERITAS PHARMACEUTICALS (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001067958-A2 | RADIOGRAPHIC ASSESSMENT OF TISSUE RESPONSE TO COMPOUNDS | VERITAS PHARMACEUTICALS (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001067959-A2 | RADIOGRAPHIC ASSESSMENT OF TISSUE RESPONSE TO COMPOUNDS | VERITAS PHARMACEUTICALS (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040170561-A1 | Functional radiographic imaging methods and agents | GPR180, TMEM120A, RXFP1 | LMNA 730/4885GAA 3902/4885ALDH1A1 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.